Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 18/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.65 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2126090 | 1.00 | PTGS2 (0.65) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL29612911 | 1.00 | PTGS2 (0.65) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL2126117 | 1.00 | PTGS2 (0.65) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL29612620 | 1.00 | PTGS2 (0.65) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL29612604 | 1.00 | PTGS2 (0.65) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL7179556 | 0.85 | PTGS2 (0.67) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL8291544 | 0.84 | PTGS2 (0.46) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL17878838 | 0.83 | PTGS2 (0.71) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL5551731 | 0.81 | PTGS2 (0.67) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL14422875 | 0.81 | PTGS2 (0.67) | PTGS2PTGS1ABCC4ABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012052180-A1 | COMBINATIONS COMPRISING DHODH INHIBITORS AND COX INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-26 | — | — | WO | claimed |
| EP-2444086-A1 | Combinations comprising DHODH inhibitors and COX inhibitors | Almirall, S.A. (ES) | 2012-04-25 | — | — | EP | claimed |
| US-20060229338-A1 | 2,3'-bipyridines derivatives as selective cox-2 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-10-12 | — | — | US | claimed |
| JP-2006517562-A | — | — | 2006-07-27 | — | — | JP | claimed |
| EP-1592666-A1 | 2,3 -BIPYRIDINES DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2005-11-09 | — | — | EP | claimed |
| WO-2004072037-A1 | 2,3'-BIPYRIDINES DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | ALMIRALL PRODESFARMA S.A. (ES) | 2004-08-26 | — | — | WO | claimed |
| US-11602515-B2 | Pharmaceutical compositions comprising dimethyl fumarate | ALMIRALL, S.A. (ES) | 2023-03-14 | — | — | US | disclosed |
| US-20210330628-A1 | Pharmaceutical Compositions Comprising Dimethyl Fumarate | ALMIRALL, S.A. (ES) | 2021-10-28 | — | — | US | disclosed |
| EP-3079666-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | ALMIRALL SA (ES) | 2021-02-03 | — | — | EP | disclosed |
| US-20200197348-A1 | Pharmaceutical Compositions Comprising Dimethyl Fumarate | ALMIRALL, S.A. (ES) | 2020-06-25 | — | — | US | disclosed |
| EP-3656379-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | Almirall S.A. (ES) | 2020-05-27 | — | — | EP | disclosed |
| EP-3641736-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | Almirall, S.A. (ES) | 2020-04-29 | — | — | EP | disclosed |
| WO-2018234584-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | ALMIRALL, S.A. (ES) | 2018-12-27 | — | — | WO | disclosed |
| EP-3079666-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | Almirall S.A. (ES) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015086467-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | ALMIRALL, S.A. (ES) | 2015-06-18 | — | — | WO | disclosed |
| WO-2012052180-A1 | COMBINATIONS COMPRISING DHODH INHIBITORS AND COX INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-26 | — | — | WO | disclosed |
| EP-2444086-A1 | Combinations comprising DHODH inhibitors and COX inhibitors | Almirall, S.A. (ES) | 2012-04-25 | — | — | EP | disclosed |
| US-20060229338-A1 | 2,3'-bipyridines derivatives as selective cox-2 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-10-12 | — | — | US | disclosed |
| EP-1592666-A1 | 2,3 -BIPYRIDINES DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004072037-A1 | 2,3'-BIPYRIDINES DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | ALMIRALL PRODESFARMA S.A. (ES) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11602515-B2 | Pharmaceutical compositions comprising dimethyl fumarate | MGAM, SI, FH | PTGS2 2276/4885PTGS1 1521/4885ABCC4 1587/4885 |
| US-20210330628-A1 | Pharmaceutical Compositions Comprising Dimethyl Fumarate | MGAM, SI, FH | PTGS2 2168/4885PTGS1 1359/4885ABCC4 1761/4885 |
| US-20200197348-A1 | Pharmaceutical Compositions Comprising Dimethyl Fumarate | MGAM, SI, FH | PTGS2 2276/4885PTGS1 1521/4885ABCC4 1587/4885 |
| US-20060229338-A1 | 2,3'-bipyridines derivatives as selective cox-2 inhibitors | PTGS2, PTGES2, PTGER2 | PTGS2 1/4885PTGS1 4/4885ABCC4 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.